(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

"Having walked in the shoes of parent, nurse, and physician, Dr. McMahon brings a very unique and vital perspective to our Board," said Melmark President and CEO Rita M. Gardner, M.P.H., LABA, BCBA, ...